Aldeyra Therapeutics, Inc.
ALDX · XNASCIK 1341235fmd_123VNW400WWGBYJQFH61F1S6X8Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2005 to Sep 30, 2026, 63 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | 13 | 16 | 30 | 44 | 25 | 45 | 47 | 29 | 48 | 26 |
| Operating income | (19) | (22) | (40) | (63) | (36) | (56) | (63) | (43) | (60) | (35) |
| Interest expense | 0 | 0 | 0 | 1 | 2 | 2 | 2 | 2 | 2 | 2 |
| Interest and investment income | 0 | 0 | 1 | 2 | 0 | 0 | 2 | 7 | 6 | 3 |
| Other non-operating income (expense) | (0) | 0 | 1 | 1 | (2) | (2) | 1 | 5 | 4 | 1 |
| Income before taxes | – | – | (39) | (62) | (38) | (58) | – | – | 56 | 34 |
| Income tax expense | 0 | 0 | 0 | (1) | (0) | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | – | – | (39) | (61) | (38) | (58) | – | – | 56 | 34 |
| Net income | (19) | (22) | (39) | (61) | (38) | (58) | (62) | (38) | (56) | (34) |
| Net income to common shareholders | – | – | – | – | – | – | – | – | – | – |